SCHEMBL12430557

SCHEMBL12430557

c1ccc2c(Sc3nc(Nc4cc(C5CC5)[nH]n4)c4ccccc4n3)cccc2c1

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 9/20 0.66
AURKB Q96GD4 5/20 0.66
SRC P12931 4/20 0.66
ULK1 O75385 1/20 0.56
PAK4 O96013 1/20 0.56
PAK1 Q13153 1/20 0.56
AURKA O14965 7/20 0.56
NTRK1 P04629 2/20 0.56
CCNA2 P20248 2/20 0.55
CDK2 P24941 2/20 0.55
IGF1R P08069 1/20 0.52
NTRK3 Q16288 1/20 0.52
NTRK2 Q16620 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430546 0.89 GSK3B (0.71) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430543 0.88 GSK3B (0.73) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430527 0.87 GSK3B (0.76) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430534 0.86 GSK3B (0.71) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430536 0.85 NTRK1 (0.64) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430545 0.83 GSK3B (0.72) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430529 0.83 GSK3B (0.68) GSK3BAURKBSRCULK1PAK4
SCHEMBL13840488 0.83 GSK3B (0.75) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430533 0.83 GSK3B (0.70) GSK3BAURKBSRCULK1PAK4
SCHEMBL12430550 0.82 GSK3B (0.61) GSK3BAURKBSRCULK1PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA GSK3B 1/4885AURKB 7/4885SRC 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.